The Pharmacy Times® Depression Resource Center is a comprehensive resource for clinical news and expert insights on treatments for the different forms of depression and its symptoms.
January 21st 2025
Esketamine targets glutamate, the most abundant neurotransmitters in the brain.
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies
1.0 Credit / Psychiatry
View More
Experts Examine Ways to Reduce Global Burden of Depression
March 10th 2022The commission “Time for United Action on Depression,” authored by 25 experts from 11 countries, seeks to unify global efforts among governments, health care providers, researchers, people living with depression, and their families to improve care and prevention, fill knowledge gaps, and increase awareness.
Read More
AbbVie Seeks FDA Approval for Cariprazine for Adjunctive Treatment of Major Depressive Disorder
February 23rd 2022In a phase 3 study, there were clinically and statistically significant changes observed from baseline to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score for patients treated with cariprazine at 1.5 mg/day versus the placebo.
Read More